Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2013

View Archived Issues

Large-scale studies link new genes to obesity

Soligenix and Intrexon enter exclusive worldwide collaboration for melioidosis

Nucleocapsid assembly effector with efficacy in reducing viral cccDNA in vitro

Genmab reports phase II data for ofatumumab combined with bendamustine

Ferring Pharmaceuticals begins two phase III trials of elobixibat

Abide Therapeutics and Merck & Co. form collaboration

GSK-1322322 shows activity against Legionella pneumophila

Gilead to commence third phase III trial of fixed-dose combination tablet for HCV infection

Acceleron and Shire decide to conclude collaboration on ACE-031

RNL BIO files IND to commence phase II trial of RNL-JointStem for osteoarthritis

Pharmacodynamics of GS-9620 tested in chronic HCV patients

Takeda presents novel CENP-E inhibitor with oncolytic activity

DM-CHOC-PEN well tolerated in phase I trial

Shionogi & Co. discloses new HIV integrase inhibitors

Novel FGFR inhibitors patented by Orion Corp.

Beta Pharma synthesizes new agents for cancer

Fibrocell Science begins phase II trial of azficel-T in new indication

CSIR discloses novel agents for bacterial infections

Lundbeck prepares new PDE9 inhibitors for neurodegenerative disorders

Bristol-Myers Squibb divulges novel NS5B inhibitors

Regeneron expands ophthalmology pipeline

Pharmaco-Kinesis reports development of combinatorial nano-drug for gliomas and other cancers

Ambrx and Bristol-Myers Squibb form new collaboration for antibody-drug conjugates

FDA expands approval of efavirenz to patients as young as 3 months

Merck & Co. gains FDA approval for Liptruzet combination tablet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026
SERCA inhibitor shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, researchers...